Carbestrol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 07:55, 27 September 2016 (→‎top: http→https for Google Books and Google News using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Carbestrol
Clinical data
ATC code
  • None
Identifiers
  • 3-Ethyl-4-(4-methoxyphenyl)-2-methylcyclohex-3-ene-1-carboxylic acid
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H22O3
Molar mass274.35478 g/mol g·mol−1
3D model (JSmol)
  • CCC1=C(CCC(C1C)C(=O)O)C2=CC=C(C=C2)OC
  • InChI=1S/C17H22O3/c1-4-14-11(2)15(17(18)19)9-10-16(14)12-5-7-13(20-3)8-6-12/h5-8,11,15H,4,9-10H2,1-3H3,(H,18,19)
  • Key:VJKVHUZOVAWKEB-UHFFFAOYSA-N

Carbestrol (developmental code names NSC-19962, ORF-2166) is a synthetic, non-steroidal estrogen of the cyclohexenecarboxylic acid group and seco analogue of doisynolic acid that was described in the literature in 1956 and developed for the treatment of prostate cancer in the 1960s but was never marketed.[1][2][3][4]

See also

References

Template:Research help

  1. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 516–. ISBN 978-1-4757-2085-3.
  2. ^ ARDUINO LJ (1964). "CARBESTROL (NSC-19962) TREATMENT OF PATIENTS WITH PROSTATIC CARCINOMA-PRELIMINARY REPORT". Cancer Chemother Rep. 39: 67–75. PMID 14201278.
  3. ^ Kogler J, Hill G, Sedransk N, Cole DR, Weiss AJ, Wilson W (1972). "Phase II study of carbestrol (NSC-19962) in patients with solid tumors". Cancer Chemother Rep. 56 (5): 641–7. PMID 4652590.
  4. ^ Raymond Eller Kirk; Donald Frederick Othmer (1980). Encyclopedia of chemical technology. Wiley. p. 672. ISBN 978-0-471-02065-3.